CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical
oncology company advancing a broad pipeline of novel product candidates
based on its Targeting Protein Therapeutics (TPTs) platform, today
announced that it will host a live conference call and webcast at 8:00
a.m. ET on Thursday, May 4, 2017 to report its first quarter 2017
financial results and provide a corporate update.
To access the conference call, please dial (844) 831-3025 (domestic) or
(315) 625-6887 (international) at least five minutes prior to the start
time and refer to conference ID 12752483. An audio webcast of the call
will also be available on the Investors & Media section of the company's
An archived webcast will be available on the Company's website
approximately two hours after the event and will be available for 30
About Eleven Biotherapeutics
Eleven Biotherapeutics, Inc. is a late-stage clinical oncology company
advancing a broad pipeline of novel product candidates based upon the
Company's TPTs platform. The Company's TPTs incorporate a
tumor-targeting antibody fragment and a protein cytotoxic payload into a
single protein molecule in order to achieve focused tumor cell killing.
The Company believes its TPT approach offers significant advantages in
treating cancer over existing antibody drug conjugate technologies. The
Company believes its TPTs provide effective tumor targeting with broader
cancer cell-killing properties than are achievable with small molecule
payloads that require tumor cell proliferation and face multi-drug
resistance mechanisms. Additionally, the Company believes that its TPT's
cancer cell-killing properties promote an anti-tumor immune response
that will potentially combine well with immune oncology drugs such as
checkpoint inhibitors. For more information please refer to the
Company's website at www.elevenbio.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170428005301/en/
Stern Investor Relations
Source: Eleven Biotherapeutics, Inc.
News Provided by Acquire Media